Evidence-based dexamethasone dosing in malignant brain tumors: what do we really know?

• Published in: Journal of neuro-oncology 2019-09, Vol.144 (2), p.249-264
• Main Authors: Jessurun, Charissa A. C., Hulsbergen, Alexander F. C., Cho, Logan D., Aglio, Linda S., Nandoe Tewarie, Rishi D. S., Broekman, Marike L. D.
• Format: Article
• Language: English
• Subjects: Anti-Inflammatory Agents - administration & dosage; Brain cancer; Brain Neoplasms - drug therapy; Brain tumors; Dexamethasone; Dexamethasone - administration & dosage; Dosage; Dose-Response Relationship, Drug; Edema; Evidence-Based Medicine; Glioma; Humans; Immunotherapy; Medicine; Medicine & Public Health; Metastases; Metastasis; Neurology; Oncology; Steroids; Survival; Systematic review; Topic Review; Tumors
• ISSN: 0167-594X; 1573-7373
• DOI: 10.1007/s11060-019-03238-4

Purpose The present study aims to conduct a systematic review of literature reporting on the dose and dosing schedule of dexamethasone (DXM) in relation to clinical outcomes in malignant brain tumor patients, with particular attention to evidence-based practice. Methods A systematic search was performed in PubMed, Embase, Web of Science, Cochrane, Academic Search Premier, and PsycINFO to identify studies that reported edema volume reduction, symptomatic relief, adverse events and survival in relation to dexamethasone dose in glioma or brain metastasis (BM) patients. Results After screening 1812 studies, fifteen articles were included for qualitative review. Most studies reported a dose of 16 mg, mostly in a schedule of 4 mg four times a day. Due to heterogeneity of studies, it was not possible to perform quantitative meta-analysis. For BMs, best available evidence suggests that higher doses of DXM may give more adverse events, but may not necessarily result in better clinical condition. Some studies suggest that higher DXM doses are associated with shorter survival in the palliative setting. For glioma, DXM may lead to symptomatic improvement, yet no studies directly compare different doses. Results regarding edema reduction and survival in glioma patients are conflicting. Conclusions Evidence on the safety and efficacy of different DXM doses in malignant brain tumor patients is scarce and conflicting. Best available evidence suggests that low DXM doses may be noninferior to higher doses in certain circumstances, but more comparative research in this area is direly needed, especially in light of the increasing importance of immunotherapy for brain tumors.